Call Us: 888-488-5750

Facebook Linkedin

That’s a wrap! VativoRx on TV

We have some great news about VativoRx.

For the past year, we’ve been working with an independent video producer to create and air a short-form video segment about how PBMs can do better. Today we can reveal two more details about that partnership:

  • The video will begin airing on PBS stations in the United States in April
  • The video was produced as a segment of Viewpoint Project with Dennis Quaid.

And, starting today, as a visitor to the VativoRx.com website, you can see the segment in full right here:

Viewpoint Project with Dennis Quaid specializes in short-form Public Television stories.  Each story highlights specific industries and topics around the world. The show highlights industry professionals and groundbreaking organizations as featured content providers.

Viewpoint Project with Dennis Quaid is created solely for viewing on Public Television stations across the US. Public Television stations receive content from organizations like NETA (National Educational Telecommunications Alliance), from locally produced material and from smaller organizations, such as “Viewpoint Project.” Viewpoint Project with Dennis Quaid operates independently and provides content to Public Television partners by way of satellite uplink.

Viewpoint episodes run as short-form segments between longer programming, generally ranging from three-to-six minutes.

We’re proud to participate in this educational project. 

Pharma Tariffs and Specialty Drug Cost Management: What Health Plans and TPAs Should Be Watching

On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.

Read More »
April 17, 2026

When Drug Negotiation Reaches Part B

For years, Medicare drug price negotiation was mostly discussed as a Part D story. That changed in January, when CMS selected 15 drugs for the third cycle of negotiation, including the first drugs payable under Medicare Part B. Negotiations take place in 2026, and any negotiated prices from this cycle take effect in 2028.

Read More »
March 27, 2026